UCB (MEX:UCBN) FFO


MEX:UCBN UCB SA MEX:UCBN
85 GF Score
Price MXN1,692.27
GF Value MXN1,417.06
! 2 Warning Signs
View Full Analysis

What is UCB FFO?

FFO (Funds from operations) only applies to REITs.

MEX:UCBN
85GF Score
UCB SA MEX:UCBN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is UCB (MEX:UCBN) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of MXN1,692.27 is trading 19.4% above its estimated GF Value™ of MXN1,417.06.

Key valuation signals for MEX:UCBN:

  • FFO:
  • GF Value™: MXN1,417.06 vs. price of MXN1,692.27 (19.4% above fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the MEX:UCBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
85GF Score

Get the complete analysis for MEX:UCBN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,692.27
Price
MXN1,417.06
GF Value